RecruitingPhase 1NCT07044271

A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants

An Open-Label, Randomized, 3-Way Crossover Study Comparing the Pharmacokinetics of Multiple Olomorasib (LY3537982) Capsules


Sponsor

Eli Lilly and Company

Enrollment

120 participants

Start Date

Jul 11, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of this study is to measure how much olomorasib gets into the bloodstream and how long it takes the body to get rid of it. Healthy participants will take olomorasib by mouth. The study will last about 7 weeks and will include 10 back-to-back overnight stays in the research center.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria3

  • Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
  • Body mass index (BMI): 18.0 to 30.0 kilograms per square meter (kg/m²), inclusive
  • Participants assigned male at birth (AMAB) or assigned female at birth (AFAB) who are individuals not of childbearing potential (INOCBP).

Exclusion Criteria3

  • Females who are lactating or of childbearing potential
  • Clinically significant history of any drug sensitivity, drug allergy, or food allergy
  • Have used or plan to use medication within 14 days or 5 half-lives, whichever is longest, prior to admission, with the exception occasional acetaminophen at doses less than or equal to 2 g/day.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOlomorasib

Single dose


Locations(2)

ICON Early Phase Services

San Antonio, Texas, United States

ICON

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07044271


Related Trials